Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary/fecal route.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
Standard dose: 5 mg orally once daily. May be taken with or without food.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years.
## Dose Adjustments
**Renal Impairment:** No dosage adjustment required.
**Hepatic Impairment:** No dosage adjustment required.
**Concomitant Use:** If used with a strong CYP3A4/P-gp inducer (e.g., rifampin), clinical response should be monitored; consider an alternative agent if glycemic control is inadequate.
## Contraindications
History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
Common: Nasopharyngitis.
Serious: Acute pancreatitis (discontinue if suspected), bullous pemphigoid, severe arthralgia, and hypersensitivity reactions. Risk of hypoglycemia is low unless used in combination with insulin or sulfonylureas (consider dose reduction of insulin/sulfonylureas).
## Key Drug Interactions
**Strong CYP3A4/P-glycoprotein inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease linagliptin plasma concentrations and therapeutic efficacy.
**Insulin/Secretagogues:** May increase the risk of hypoglycemia.
## Monitoring
Monitor HbA1c (typically every 3–6 months), periodic renal function, and symptoms of pancreatitis (e.g., persistent severe abdominal pain). Assess skin for blistering if bullous pemphigoid is suspected.
## Clinical Pearls
- Unique among DPP-4 inhibitors because it is primarily excreted hepatically rather than renally, requiring no renal dose adjustments.
- Does not cause weight gain.
- Should not be used in patients with Type 1 diabetes (not effective) or for the treatment of diabetic ketoacidosis.
- If a dose is missed, take it as soon as identified; do not take a double dose on the same day.
***
**Educational Disclaimer:** This information is for educational purposes and does not substitute professional medical advice. Always verify current prescribing information, local clinical guidelines, and patient-specific factors with the official manufacturer labeling or a clinical decision support system before prescribing or administering medication.
